EKF Diagnostics Holdings PLC (DE:LYF)
FRANKFURT:LYF
LYF Stock Chart & Stats
€0.31
€0.01(3.92%)
At close: 4:00 PM EST
€0.31
€0.01(3.92%)
Day’s Range― - ―
52-Week Range€0.23 - €0.34
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€132.60M
Enterprise Value€100.71M
Total Cash (Recent Filing)€15.83M
Total Debt (Recent Filing)€1.39M
Price to Earnings (P/E)55.8
Beta-0.11
Next Earnings
Sep 22, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding430,503,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.85
Price to Book (P/B)1.71
Price to Sales (P/S)2.30
P/FCF Ratio14.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.40Price Target Upside30.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€630.27K
Bulls Say, Bears Say
Bulls Say
Debt ManagementThe business is now debt-free, having fully repaid all bank borrowings.
Financial PerformanceEKF reports a positive 1Q25 trading update with the business on track to meet current FY25 market expectations for revenues.
Financial StabilityThe company completed a £1m share buyback, purchasing 4.6 million shares, which reflects confidence in its financial position.
Bears Say
Revenue DeclineFY24 revenues declined 4.6%, which was lower than prior consensus.
EKF Diagnostics Holdings News
LYF FAQ
What was EKF Diagnostics Holdings PLC’s price range in the past 12 months?
EKF Diagnostics Holdings PLC lowest stock price was €0.23 and its highest was €0.34 in the past 12 months.
What is EKF Diagnostics Holdings PLC’s market cap?
EKF Diagnostics Holdings PLC’s market cap is €132.60M.
When is EKF Diagnostics Holdings PLC’s upcoming earnings report date?
EKF Diagnostics Holdings PLC’s upcoming earnings report date is Sep 22, 2026 which is in 108 days.
How were EKF Diagnostics Holdings PLC’s earnings last quarter?
EKF Diagnostics Holdings PLC released its earnings results on Mar 24, 2026. The company reported €0.007 earnings per share for the quarter, the consensus estimate of €0.007 by €0.
Is EKF Diagnostics Holdings PLC overvalued?
According to Wall Street analysts EKF Diagnostics Holdings PLC’s price is currently Undervalued.
Does EKF Diagnostics Holdings PLC pay dividends?
EKF Diagnostics Holdings PLC does not currently pay dividends.
What is EKF Diagnostics Holdings PLC’s EPS estimate?
EKF Diagnostics Holdings PLC’s EPS estimate is 0.01.
How many shares outstanding does EKF Diagnostics Holdings PLC have?
EKF Diagnostics Holdings PLC has 430,503,100 shares outstanding.
What happened to EKF Diagnostics Holdings PLC’s price movement after its last earnings report?
EKF Diagnostics Holdings PLC reported an EPS of €0.007 in its last earnings report, expectations of €0.007. Following the earnings report the stock price went down -1.493%.
Which hedge fund is a major shareholder of EKF Diagnostics Holdings PLC?
Currently, no hedge funds are holding shares in DE:LYF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EKF Diagnostics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€0.40 (30.30% Upside)
€0.40 (30.30% Upside)
Insider Transactions
Sold Shares
Worth €62.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.88%
12-Months-Change
Fundamentals
Return on Equity
3.01%
Trailing 12-Months
Asset Growth
-0.74%
Trailing 12-Months
Company Description
EKF Diagnostics Holdings PLC
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
LYF Stock 12 Month Forecast
Average Price Target
€0.40
▲(30.30% Upside)
Technical Analysis
Options Prices
Currently, No data available
---